ATE290881T1 - Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten - Google Patents

Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten

Info

Publication number
ATE290881T1
ATE290881T1 AT01907655T AT01907655T ATE290881T1 AT E290881 T1 ATE290881 T1 AT E290881T1 AT 01907655 T AT01907655 T AT 01907655T AT 01907655 T AT01907655 T AT 01907655T AT E290881 T1 ATE290881 T1 AT E290881T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
certain types
ferritin antibodies
fragment
Prior art date
Application number
AT01907655T
Other languages
English (en)
Inventor
Jean Kadouche
Rafael Levy
Original Assignee
Monoclonal Antibodies Therapeu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monoclonal Antibodies Therapeu filed Critical Monoclonal Antibodies Therapeu
Application granted granted Critical
Publication of ATE290881T1 publication Critical patent/ATE290881T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01907655T 2000-01-20 2001-01-19 Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten ATE290881T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0000718A FR2804027B1 (fr) 2000-01-20 2000-01-20 Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
PCT/FR2001/000192 WO2001052889A1 (fr) 2000-01-20 2001-01-19 Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers

Publications (1)

Publication Number Publication Date
ATE290881T1 true ATE290881T1 (de) 2005-04-15

Family

ID=8846119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907655T ATE290881T1 (de) 2000-01-20 2001-01-19 Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten

Country Status (10)

Country Link
US (2) US7153506B2 (de)
EP (1) EP1165134B1 (de)
JP (1) JP2003520250A (de)
AT (1) ATE290881T1 (de)
AU (1) AU3556901A (de)
CA (1) CA2387383C (de)
DE (1) DE60109359T2 (de)
ES (1) ES2239126T3 (de)
FR (1) FR2804027B1 (de)
WO (1) WO2001052889A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119591703A (zh) * 2023-09-08 2025-03-11 东莞市朋志生物科技有限公司 一种抗铁蛋白的抗体及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033129T2 (en) 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
EP1563851A1 (de) * 2004-02-17 2005-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Verbindung eines Antikörpers mit einer kationischen Emulsion als Drogenlieferungs-System
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
GB0420566D0 (en) * 2004-09-16 2004-10-20 Sec Dep For Environment Food & Assay method
JP2009508936A (ja) * 2005-09-20 2009-03-05 イッサム リサーチ ディベロップメント カンパニー 活性物質の標的化送達用ナノ粒子
GB0612825D0 (en) * 2006-06-28 2006-08-09 Iti Scotland Ltd Analyte detection
GB0616508D0 (en) * 2006-08-18 2006-09-27 Iti Scotland Ltd Analyte manipulation and detection
US20090053736A1 (en) * 2007-08-21 2009-02-26 Mattingly Phillip G Homogeneous Chemiluminescent Immunoassay for Analysis of Iron Metalloproteins
CA2696634A1 (en) * 2007-09-19 2009-03-26 Monoclonal Antibodies Therapeutics Monoclonal antibodies against human acidic and basic ferritins and nucleotide and amino acid sequences thereof
US8728477B2 (en) 2007-09-19 2014-05-20 Immune Pharmaceuticals Ltd. Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
AU3783893A (en) * 1992-02-28 1993-09-13 Stanley E. Order Use of aggregated proteins to prolong retention time of a therapeutic agent adjacent a targeted site such as a tumor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119591703A (zh) * 2023-09-08 2025-03-11 东莞市朋志生物科技有限公司 一种抗铁蛋白的抗体及其应用

Also Published As

Publication number Publication date
CA2387383A1 (fr) 2001-07-26
ES2239126T3 (es) 2005-09-16
CA2387383C (fr) 2008-10-21
FR2804027A1 (fr) 2001-07-27
DE60109359T2 (de) 2006-04-13
US7153506B2 (en) 2006-12-26
US20020106324A1 (en) 2002-08-08
DE60109359D1 (de) 2005-04-21
AU3556901A (en) 2001-07-31
US20070042447A1 (en) 2007-02-22
FR2804027B1 (fr) 2002-08-30
WO2001052889A1 (fr) 2001-07-26
EP1165134A1 (de) 2002-01-02
EP1165134B1 (de) 2005-03-16
JP2003520250A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
CY1107453T1 (el) Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
DE69433406T2 (de) Antikörper gegen cd40
BR0011838A (pt) Elementos misturadores estáticos empilhados
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE177754T1 (de) Fragmente von prion proteinen.
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
DE60032486D1 (de) Prion protein peptide und deren verwendung
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
ES2098274T3 (es) Anticuerpos monoclonales.
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
DE69622259D1 (de) Cd40 bindendes protein zur stimulierung der immunantwort
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
MX2025012203A (es) Formulaciones farmaceuticas que contienen anticuerpos anti-ox40l
GB0004576D0 (en) Proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165134

Country of ref document: EP

REN Ceased due to non-payment of the annual fee